Sign in
Taking people in United StatesNo phase

Tests a treatment to improve insulin response in adults with kidney disease and diabetes

Tests insulin resensitization in adults with kidney disease and type 2 diabetes.

Key facts

Who runs it
Well Cell Global
Where
Phoenix and Scottsdale, United StatesSee the 2 sites
Trial code
Registry title
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
Status
Recruiting
People taking part
120 people, planned
Started
14 Oct 2025
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Physiologic Insulin Resensitization (PIR)
Record updated
4 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic kidney disease (stage 3b, 4 or 5) and type 2 diabetes for at least 6 months.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Chronic kidney disease stage 3b, 4 or 5, and type 2 diabetes for 6 months or longer.
Earlier treatment
A stable treatment plan for any complications for the past 6 months. Diabetes tablets, injections, insulin and GLP-1 receptor agonists are allowed.

Main reasons for not taking part

  • Treatment for cancer in the past 2 years
  • Pregnant, planning pregnancy or breastfeeding
  • Positive test for HIV, HBsAg or HCV viral load
  • Currently on dialysis
  • Severe low blood sugar needing urgent care in the past 6 months

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Is age 18 or older (male or female)
  • Have a documented diagnosis of CKD stage 3b, 4, or 5 and T2DM of 6 months or greater prior to screening. Patients may have treatment regimens associated with T2DM that include diabetic oral and/or injectable medications including insulin and/or GLP-1 receptor agonists
  • In the opinion of the Investigator, has been on an appropriate, stable regimen for management of any complications present for the past six (6) months
  • In the opinion of the Investigator, is able to do all of the following:; Provide valid informed consent; Understand and comply with study procedures as presented in the consent process; Has the capacity or support to attend all required visits
  • If female, the subject must meet either of the following sets of conditions:; o Is of non-childbearing potential, defined as meeting either of the following criteria:
  • Age ≥50 years and post-menopausal for at least one (1) year
  • Surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
  • Is of childbearing potential and meets both of the following criteria:; Has a negative serum pregnancy test (beta-human chorionic gonadotropin) at screening; Agrees to practice an acceptable method of birth control (contraception) from screening until at least 30 days after last study treatment

Who cannot take part

  • Has in the past two (2) years received treatment for a malignancy
  • Has in the past one (1) year used non-prescription opioids or psychoactive drugs
  • Has at screening a positive test for HIV (4th gen. screen), HBsAg, or HCV viral load
  • Has - in the opinion of the Investigator - psychiatric, behavioral, cognitive and/or clinical dysfunction (whether or not related to known medical illness or drug / alcohol use) that would affect the subject's safety and/or compliance
  • Has in the past six (6) months had a hypoglycemic event requiring urgent care and/or administration of glucagon, osteocalcin, or parenteral glucose, unless approved for enrollment by the Medical Monitor
  • Has within the past one (1) month participated in a clinical study involving either of the following:; An investigational drug or procedure for any clinical indication; An investigation method for glucose control using approved agents
  • Has at screening, one or more of the following abnormal lab results:; Hb <8 g/dL; WBC <2,000/µL; Platelets <50,000/µL; ALT, AST, or Alkaline Phosphatase >5x ULN; ALT or AST >2.5x ULN, and Total Bilirubin >2x ULN; Serum albumin <3 g/dL
  • Current pregnancy or intends to become pregnant during the study
  • Is nursing or is planning to nurse during the study
  • Is on active dialysis at time of screening

Where in United States

  • Arizona Kidney Disease and Hypertension CenterPhoenix, United StatesContact: Cynthia Carrizoza, MS, CCRPTaking people
  • Innovative Diabetic CenterScottsdale, United StatesContact: Austin Mill, ACNP-BCTaking people

About the trial

What the trial wants to find out

The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).

The 2 groups in the trial

  • Physiologic Insulin Resensitization (PIR) GroupTreatment being tested

    Subject to receive Physiologic Insulin Resensitization (PIR)

    Treatment: Physiologic Insulin Resensitization (PIR)

  • Standard of Care (SOC) GroupNo study treatment, for comparison

    Subjects will receive standard of care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Randomized, Open Label Study to Examine the Outcomes of Physiologic Insulin Resensitization in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
Plain-language title
Tests a treatment to improve insulin response in adults with kidney disease and diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 August 2026